ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,959,400 | -10.8% | 85,000 | -15.0% | 2.62% | -11.1% |
| Q2 2023 | $8,925,000 | -24.3% | 100,000 | -9.1% | 2.95% | -15.5% |
| Q1 2023 | $11,794,000 | -25.7% | 110,000 | -15.4% | 3.49% | -48.6% |
| Q4 2022 | $15,877,000 | +61.8% | 130,000 | +36.8% | 6.78% | +146.2% |
| Q3 2022 | $9,810,000 | +40.7% | 95,000 | +26.7% | 2.75% | -24.2% |
| Q2 2022 | $6,972,000 | -57.6% | 75,000 | -46.4% | 3.63% | +1.8% |
| Q1 2022 | $16,430,000 | -35.7% | 140,000 | -26.3% | 3.57% | -61.1% |
| Q4 2021 | $25,561,000 | +33.6% | 190,000 | +58.3% | 9.16% | +63.8% |
| Q3 2021 | $19,127,000 | +7.7% | 120,000 | -11.1% | 5.59% | +14.6% |
| Q2 2021 | $17,759,000 | +2.1% | 135,000 | 0.0% | 4.88% | +19.4% |
| Q1 2021 | $17,399,000 | -0.6% | 135,000 | +28.6% | 4.09% | +4.8% |
| Q4 2020 | $17,512,000 | -12.7% | 105,000 | -19.2% | 3.90% | -32.7% |
| Q3 2020 | $20,062,000 | +108.7% | 130,000 | +100.0% | 5.80% | +128.5% |
| Q2 2020 | $9,614,000 | -43.1% | 65,000 | -56.7% | 2.54% | -43.4% |
| Q1 2020 | $16,892,000 | -39.3% | 150,000 | -25.0% | 4.48% | -15.5% |
| Q4 2019 | $27,824,000 | +92.6% | 200,000 | +33.3% | 5.30% | +44.0% |
| Q3 2019 | $14,448,000 | -44.2% | 150,000 | -33.3% | 3.68% | -31.5% |
| Q2 2019 | $25,909,000 | -61.4% | 225,000 | -60.5% | 5.37% | -69.3% |
| Q1 2019 | $67,090,000 | +756.7% | 570,000 | +356.0% | 17.53% | +516.7% |
| Q4 2018 | $7,831,000 | -50.9% | 125,000 | -44.4% | 2.84% | -16.1% |
| Q3 2018 | $15,944,000 | +37.0% | 225,000 | +28.6% | 3.39% | -1.1% |
| Q2 2018 | $11,641,000 | +27.1% | 175,000 | +25.0% | 3.43% | +85.0% |
| Q1 2018 | $9,156,000 | -8.6% | 140,000 | -44.0% | 1.85% | -21.2% |
| Q4 2017 | $10,015,000 | +38.1% | 250,000 | +25.0% | 2.35% | +52.5% |
| Q3 2017 | $7,250,000 | +446.3% | 200,000 | +100.0% | 1.54% | +302.1% |
| Q2 2016 | $1,327,000 | -22.8% | 100,000 | +2.9% | 0.38% | -50.5% |
| Q3 2015 | $1,719,000 | +52.5% | 97,135 | +52.4% | 0.77% | +112.1% |
| Q2 2015 | $1,127,000 | – | 63,739 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |